“It is time to offer genetic screening of BRCA1 and BRCA2 genes to every women”
Dr. Marie-Claire King (discoverer of BRCA1 gene)
Genetics of pancreatic cancer
Pancreatic cancer is one of the most deadliest cancer type, therefore early diagnostics of this disease is of the utmost importance. Persons with family history of pancreatic cancer are at increased risk of developing pancreatic cancer.
Around 10% of pancreatic cancer (adenocarcinoma) cases are due inherited mutations in known high/medium cancer risk genes, as well as due to as yet undefined genetic factors.
Hereditary pancreatic cancer mostly is part of other cancer predisposing syndromes (such as Peutz-Jeghers syndrome, hereditary melanoma syndrome and others).
There are at least 13 known genes which mutations confers increased risk of pancreatic cancer.
Oncogenetic testing helps to evaluate individual cancer risk and choose the most appropriate health care. Established management, screening and prevention options help to avoid cancer or detect changes at the earliest and the most curable stages.
Hereditary pancreatic cancer genes
Comprehensive oncogenetic test of gene panels using modern next generation sequencing (NGS) technology is the most precise method for genetic ovarian cancer risk assessment.
A single comprehensive genetic ONCORISK61 test evaluate cancer predisposing mutations in 61 genes at once, at least 13 of which are associated with increased pancreatic cancer risk (mutations in other genes are associated with other cancer risk, such as breast, ovarian, uterine, colorectal, stomach, skin, prostate): BRCA1, BRCA2, TP53, PTEN, STK11, CDH1, PALB2,ATM, BRIP1, BARD1, CHEK2, RAD51C, RAD51D, MLH1, MSH2, MSH6, PMS2, EPCAM,MUTYH, APC, BMPR1A, SMAD4, GREM1, POLD1, POLE, AXIN2, NTHL1, MSH3, NF1, SMARCA4, NBN, MITF, BAP1, CDKN2A, CDK4.